The Minister of Industry and Mineral Resources inspected the production operations at the Arabio Pharmaceuticals Factory in Makkah
Makkah,: Gulf Tech News
In recognition of the vital role that the vaccine and biopharmaceutical industry plays in the Kingdom of Saudi Arabia, HE Mr. Bandar bin Ibrahim Al-Khorayef, Minister of Industry and Mineral Resources, recently inspected the Arabio factory in Makkah. This visit underscores the significant advancements that this sector has achieved in recent years.
His Excellency and the accompanying delegation attentively received a comprehensive presentation from Arabio CEO Dr. Abdulrahman Almutairi. The presentation highlighted the company’s current status and outlined its strategic plans for the future in the production of biological preparations. Additionally, it addressed initiatives to enhance facilities and increase the engagement of Saudi professionals within the sector.
The inspection visit is aligned with the Ministry’s commitment to fostering growth and enhancing competitiveness within the industrial sector. The National Industrial Strategy is dedicated to empowering domestic industrial enterprises and promoting their development, particularly in high-potential sectors such as pharmaceuticals and vaccine production. This initiative aims to achieve self-sufficiency and strengthen our industrial capabilities.
The vaccine and biopharmaceutical industry in Saudi Arabia has undergone substantial advancements in recent years. Aligned with Vision 2030, the Kingdom is actively pursuing initiatives to establish itself as a prominent center for the manufacturing of medicines, vaccines, and medical devices in the region. In this context, Arabio Pharmaceutical Products Company has emerged as a significant model, illustrating the growth and development of the pharmaceutical sector in the Kingdom through its advanced capabilities and efficient production processes.
Arabio has a robust annual packaging capacity, which includes 140 million multi-dose vials, 24 million single-dose vials, 20 million pre-filled syringes, 15 million single-dose vials, and 14 million pre-filled syringes. This remarkable capacity enables us to support approximately 65% of the vaccines included in the Saudi Expanded Program for Immunization and 79% of other vaccines.
